与标准的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗给药间隔相比，6至7周的给药间隔可产生更高的抗体反应。
A Higher Antibody Response Is Generated With a 6- to 7-Week (vs Standard) Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Dosing Interval.
作者信息
Grunau Brian, Asamoah-Boaheng Michael, Lavoie Pascal M, Karim Mohammad Ehsanul, Kirkham Tracy L, Demers Paul A, Barakauskas Vilte, Marquez Ana Citlali, Jassem Agatha N, O'Brien Sheila F, Drews Steven J, Haig Scott, Cheskes Sheldon, Goldfarb David M
机构信息
Centre for Health Evaluation & Outcome Sciences, University of British Columbia, Canada.
Department of Emergency Medicine, University of British Columbia, Canada.
出版信息
Clin Infect Dis. 2022 Aug 24;75(1):e888-e891. doi: 10.1093/cid/ciab938.
Abstract
The optimal dosing interval for severe acute respiratory syndrome coronavirus 2 vaccines remains controversial. In this prospective study, we compared serology results of paramedics vaccinated with mRNA vaccines at the recommended short (17-28 days) vs long (42-49 days) interval. We found that a long dosing interval resulted in higher spike, receptor binding domain, and spike N terminal domain antibody concentrations.
摘要
严重急性呼吸综合征冠状病毒2疫苗的最佳给药间隔仍存在争议。在这项前瞻性研究中，我们比较了按推荐的短间隔（17 - 28天）和长间隔（42 - 49天）接种mRNA疫苗的护理人员的血清学结果。我们发现，较长的给药间隔会导致更高的刺突蛋白、受体结合结构域和刺突蛋白N末端结构域抗体浓度。
相似文献
1
A Higher Antibody Response Is Generated With a 6- to 7-Week (vs Standard) Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Dosing Interval.与标准的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗给药间隔相比，6至7周的给药间隔可产生更高的抗体反应。
Clin Infect Dis. 2022 Aug 24;75(1):e888-e891. doi: 10.1093/cid/ciab938.
2
High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.新型冠状病毒刺突蛋白受体结合域线性表位在 COVID-19 mRNA 疫苗接种者中的高分辨率线性表位作图。
Microbiol Spectr. 2021 Dec 22;9(3):e0096521. doi: 10.1128/Spectrum.00965-21. Epub 2021 Nov 10.
3
Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.真实世界中衰弱老年人接受延长间隔和异源 COVID-19 mRNA 疫苗接种后的血清学反应（UNCoVER）：一项前瞻性观察队列研究的中期报告。
Lancet Healthy Longev. 2022 Mar;3(3):e166-e175. doi: 10.1016/S2666-7568(22)00012-5. Epub 2022 Feb 23.
4
Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals.接种疫苗人群中 SARS-CoV-2 病毒中和抗体滴度与刺突抗体和 ACE2 抑制的相关性。
Microbiol Spectr. 2022 Oct 26;10(5):e0131522. doi: 10.1128/spectrum.01315-22. Epub 2022 Sep 19.
5
Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.在真实环境中评估灭活 COVID-19 疫苗诱导的 SARS-CoV-2 特异性体液和细胞免疫应答的特征。
Front Immunol. 2021 Dec 22;12:802858. doi: 10.3389/fimmu.2021.802858. eCollection 2021.
6
Neutralizing Antibody Response to Pseudotype Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Differs Between mRNA-1273 and BNT162b2 Coronavirus Disease 2019 (COVID-19) Vaccines and by History of SARS-CoV-2 Infection.针对 SARS-CoV-2（新冠病毒）的假型中和抗体反应在 mRNA-1273 和 BNT162b2 两种 COVID-19 疫苗之间存在差异，且与 SARS-CoV-2 感染史有关。
Clin Infect Dis. 2022 Aug 24;75(1):e827-e837. doi: 10.1093/cid/ciab1038.
7
Quantitative SARS-CoV-2 anti-spike responses to Pfizer-BioNTech and Oxford-AstraZeneca vaccines by previous infection status.根据既往感染状况，定量检测辉瑞-生物科技和牛津-阿斯利康疫苗对 SARS-CoV-2 刺突蛋白的抗体反应。
Clin Microbiol Infect. 2021 Oct;27(10):1516.e7-1516.e14. doi: 10.1016/j.cmi.2021.05.041. Epub 2021 Jun 7.
8
Hybrid Immunity Shifts the Fc-Effector Quality of SARS-CoV-2 mRNA Vaccine-Induced Immunity.杂合免疫改变了 SARS-CoV-2 mRNA 疫苗诱导免疫的 Fc 效应子质量。
mBio. 2022 Oct 26;13(5):e0164722. doi: 10.1128/mbio.01647-22. Epub 2022 Aug 24.
9
Immunogenicity of a vaccinia virus-based severe acute respiratory syndrome coronavirus 2 vaccine candidate.基于天花病毒的严重急性呼吸综合征冠状病毒 2 疫苗候选物的免疫原性。
Front Immunol. 2022 Jul 22;13:911164. doi: 10.3389/fimmu.2022.911164. eCollection 2022.
10
Are SARS-CoV-2 Antibodies Detectable in Human Milk After Vaccination Against COVID-19?接种 COVID-19 疫苗后，人乳中能否检测到 SARS-CoV-2 抗体？
J Pediatric Infect Dis Soc. 2022 Apr 30;11(4):126. doi: 10.1093/jpids/piac024.
引用本文的文献
1
The effect of sleep and shift work on the primary immune response to messenger RNA-based COVID-19 vaccination.睡眠和轮班工作对基于信使核糖核酸的新冠疫苗接种的初次免疫反应的影响。
J Sleep Res. 2025 Aug;34(4):e14431. doi: 10.1111/jsr.14431. Epub 2024 Dec 10.
2
Comparison Study of the Bio-Plex and Meso Scale Multiplexed SARS-CoV-2 Serology Assays Reveals Evidence of Diminished Host Antibody Responses to SARS-CoV-2 after Monoclonal Antibody Treatment.Bio-Plex和Meso Scale多重SARS-CoV-2血清学检测的比较研究揭示了单克隆抗体治疗后宿主对SARS-CoV-2抗体反应减弱的证据。
Pathog Immun. 2024 Aug 15;9(2):58-78. doi: 10.20411/pai.v9i2.715. eCollection 2024.
3
Deviation from the recommended schedule: optimal dosing interval for a two-dose vaccination programme.偏离推荐时间表：两剂次疫苗接种计划的最佳给药间隔
R Soc Open Sci. 2024 Jul 3;11(7):231971. doi: 10.1098/rsos.231971. eCollection 2024 Jul.
4
Factors impacting antibody kinetics, including fever and vaccination intervals, in SARS-CoV-2-naïve adults receiving the first four mRNA COVID-19 vaccine doses.影响 SARS-CoV-2 初免成年人接受前四剂 mRNA COVID-19 疫苗时抗体动力学的因素，包括发热和疫苗接种间隔。
Sci Rep. 2024 Mar 27;14(1):7217. doi: 10.1038/s41598-024-57931-0.
5
A multiprovincial retrospective analysis of the incidence of myocarditis or pericarditis after mRNA vaccination compared to the incidence after SARS-CoV-2 infection.一项多省份的回顾性分析，对比了mRNA疫苗接种后与SARS-CoV-2感染后心肌炎或心包炎的发病率。
Heliyon. 2024 Feb 19;10(5):e26551. doi: 10.1016/j.heliyon.2024.e26551. eCollection 2024 Mar 15.
6
The effect of dose-interval on antibody response to mRNA COVID-19 vaccines: a prospective cohort study.剂量间隔对COVID-19 mRNA疫苗抗体反应的影响：一项前瞻性队列研究。
Front Immunol. 2024 Feb 16;15:1330549. doi: 10.3389/fimmu.2024.1330549. eCollection 2024.
7
Development of COVID-19 vaccine policy - United States, 2020-2023.COVID-19 疫苗政策的制定 - 美国，2020-2023 年。
Vaccine. 2024 Sep 17;42 Suppl 3(Suppl 3):125512. doi: 10.1016/j.vaccine.2023.12.022. Epub 2023 Dec 29.
8
Rapid transient and longer-lasting innate cytokine changes associated with adaptive immunity after repeated SARS-CoV-2 BNT162b2 mRNA vaccinations.与重复接种 SARS-CoV-2 BNT162b2 mRNA 疫苗后适应性免疫相关的快速瞬时和更持久的固有细胞因子变化。
Front Immunol. 2023 Nov 27;14:1292568. doi: 10.3389/fimmu.2023.1292568. eCollection 2023.
9
Eleven-month SARS-CoV-2 binding antibody decay, and associated factors, among mRNA vaccinees: implications for booster vaccination.mRNA疫苗接种者中11个月的新冠病毒结合抗体衰减情况及相关因素：对加强疫苗接种的影响
Access Microbiol. 2023 Nov 28;5(11). doi: 10.1099/acmi.0.000678.v3. eCollection 2023.
10
Booster Immunization Improves Memory B Cell Responses in Older Adults Unresponsive to Primary SARS-CoV-2 Immunization.加强免疫可改善对原发性SARS-CoV-2免疫无反应的老年人的记忆B细胞反应。
Vaccines (Basel). 2023 Jul 4;11(7):1196. doi: 10.3390/vaccines11071196.
本文引用的文献
1
Extended interval BNT162b2 vaccination enhances peak antibody generation.延长间隔接种BNT162b2疫苗可增强抗体峰值生成。
NPJ Vaccines. 2022 Jan 27;7(1):14. doi: 10.1038/s41541-022-00432-w.
2
Differential Antibody Response to mRNA COVID-19 Vaccines in Healthy Subjects.健康受试者对 mRNA COVID-19 疫苗的抗体反应差异。
Microbiol Spectr. 2021 Sep 3;9(1):e0034121. doi: 10.1128/Spectrum.00341-21. Epub 2021 Aug 4.
3
Evidence for antibody as a protective correlate for COVID-19 vaccines.针对 COVID-19 疫苗，抗体作为一种保护相关因素的证据。
Vaccine. 2021 Jul 22;39(32):4423-4428. doi: 10.1016/j.vaccine.2021.05.063. Epub 2021 May 24.
4
Public health impact of delaying second dose of BNT162b2 or mRNA-1273 covid-19 vaccine: simulation agent based modeling study.延迟接种第二剂BNT162b2或mRNA-1273新冠疫苗对公共卫生的影响：基于模拟代理的建模研究
BMJ. 2021 May 12;373:n1087. doi: 10.1136/bmj.n1087.
5
Evaluation of COVID-19 vaccination strategies with a delayed second dose.评估第二剂接种时间延迟的 COVID-19 疫苗接种策略。
PLoS Biol. 2021 Apr 21;19(4):e3001211. doi: 10.1371/journal.pbio.3001211. eCollection 2021 Apr.
6
Short or Long Interval between Priming and Boosting: Does It Impact on the Vaccine Immunogenicity?初次免疫和加强免疫之间的间隔长短：是否会影响疫苗免疫原性？
Vaccines (Basel). 2021 Mar 20;9(3):289. doi: 10.3390/vaccines9030289.
7
Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2.先前感染过 SARS-CoV-2 的个体对 BNT162b2 mRNA 疫苗的抗体反应。
Nat Med. 2021 Jun;27(6):981-984. doi: 10.1038/s41591-021-01325-6. Epub 2021 Apr 1.
8
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.一剂接种和加强针接种时间对 ChAdOx1 nCoV-19（阿斯利康）疫苗免疫原性和有效性的影响：四项随机试验的 pooled 分析。
Lancet. 2021 Mar 6;397(10277):881-891. doi: 10.1016/S0140-6736(21)00432-3. Epub 2021 Feb 19.
9
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.mRNA-1273 新型冠状病毒疫苗的有效性和安全性。
N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.
10
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.BNT162b2 mRNA 新冠病毒疫苗的安全性和有效性。
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.
Zotero 插件